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A B S T R A C T
Objective: Evidence indicates that the pathophysiology of adult psychosis involves immune dysregulation, but its
associations with stress are often not considered. The inflammatory cytokine interleukin (IL)-18, which is ele-
vated in adult schizophrenia, is suggested to be sensitive to stress. We compared the associations of IL-18 with
cortisol and clinical variables in adolescents with early-onset psychosis (EOP) aged 12–18 years and age-mat-
ched healthy controls (HC).
Method: We measured serum IL-18, IL-18 binding protein (IL-18BP), IL-18 receptor accessory protein (IL-
18RAP), IL-18 receptor 1 (IL-18R1) and cortisol, and calculated the IL-18/IL-18BP ratio in patients (n= 31) and
HC (n= 60). Psychotic symptoms were assessed using the Positive and Negative Syndrome Scale and depressive
symptoms by the Mood and Feelings Questionnaire-Child version (MFQ-C). Bivariate correlation analysis was
used to explore relationships between IL-18/IL-18BP ratio and cortisol, depression and other clinical char-
acteristics. Hierarchical multiple linear regression analysis was used to assess their individual contributions to
the variance of the IL-18/IL-18BP ratio.
Results: Patients had significantly higher IL-18 levels and IL-18/IL-18BP ratios than HC, but similar IL-18BP, IL-
18RAP and IL-18R1. Both cortisol (R2 change= 0.05) and the MFQ-C score (R2 change=0.09) contributed
significantly to the variance in IL-18/IL-18BP ratios after controlling for confounders.
Conclusion: We found increased IL-18 system activity in adolescents with EOP. Cortisol and depressive symp-
toms each contributed to the variance in the IL-18/IL-18BP ratio. Our findings support activation of in-
flammatory pathways in adolescent psychosis and suggest interactions between stress, inflammation and de-
pressive symptoms in EOP.
1. Introduction
Immune system dysregulation is suggested to play a role in the
pathogenesis of psychosis-spectrum disorders, as evaluated by genetic
(Sekar et al., 2016; Stefansson et al., 2009), epidemiological (Benros
et al., 2011; Brown and Derkits, 2010) and clinical studies of in-
flammatory markers in blood (Goldsmith et al., 2016) and
cerebrospinal fluid (Wang and Miller, 2018). However, most of the
evidence of a pro-inflammatory status in people with psychosis has
been obtained in adults, and even in meta-analyses of adult medication-
naïve first episode psychosis (FEP) heterogeneity among included stu-
dies introduce limitations (Fraguas et al., 2019). There are also in-
dications that adolescent-onset FEP features a higher pro-inflammatory
status than adult-onset FEP (Moreno et al., 2019). Further, few studies
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have explored immune dysregulation in psychosis and relationship to
psychological stress and activation of hypothalamic-pituitary-adrenal
(HPA) axis (Rodrigues-Amorim et al., 2017).
Psychological stress, a common risk factor for many physical and
psychiatric illnesses, is known to influence the immune system
(Fagundes et al., 2013). Apart from its involvement with the sympa-
thetic nervous system and the HPA axis, the molecular basis of how
psychological stress influence activation of immunological and in-
flammatory pathways is not clear (Deak et al., 2017). In patients with
schizophrenia (SCZ), a disrupted cortisol-immune interaction has been
described, with HPA-axis impairment and increased immune activation
and inflammation in experimental psychological stress paradigms
(Chiappelli et al., 2016; Glassman et al., 2018). Recent studies indicate
that the cytokine interleukin (IL)-18 might be involved in these pro-
cesses (Sugama and Conti, 2008). IL-18 is a major product of the nu-
cleotide-binding domain and leucine-rich repeat containing family
member pyrin domain-containing (NLRP)3 inflammasome, which is
suggested to be responsible for translating endogenous and exogenous
stress signals into inflammatory responses (Herman and Pasinetti,
2018). In major depression, a stress-associated psychiatric disorder, it
was reported that the NLRP3 inflammasome is activated in blood cells
from patients (Alcocer-Gomez et al., 2014).
The stress-sensitive NLRP3 inflammasome is proposed as a central
player in priming of microglial cells, inducing lowered threshold for
activation and amplified release of IL-18 and IL-1β in the CNS (Herman
and Pasinetti, 2018). As a brain resident macrophage, microglia surveys
and elicits immune responses, in addition to serving homeostatic
functions. If persistently activated microglia can promote neuroin-
flammation, unregulated synaptic pruning, loss of synaptic architecture
and neurodegeneration (Salter and Stevens, 2017), which may be re-
levant to psychiatric disorders. The central nervous system (CNS) is
particularly sensitive to the effects of IL-18 due to widespread expres-
sion of receptors, which includes regions involved in mood regulation
(Alboni et al., 2010). In homeostatic concentrations, IL-18 support
neurons and enhance long-term potentiation, but in abundance IL-18
can alter synaptic activity and cytoarchitecture in the brain (Herman
and Pasinetti, 2018).
Although genetic (Liu et al., 2011; Shirts et al., 2008), clinical
(Orhan et al., 2018; Tanaka et al., 2000; Zhang et al., 2016, 2013) and
functional studies (Reale et al., 2011) support a potential role of IL-18
in adult patients with SCZ, alterations in the IL-18 system are poorly
described in adolescents with early-onset psychosis (EOP) (defined as
psychosis with onset prior to 18 years of age). A small recent study of
genetic alterations of the cytokine system in adolescents with EOP re-
ported increased expression of IL-18 mRNA, but a greater decrease in
mRNA expression of IL-18 receptor type 1 (IL-18R1), suggesting re-
duced overall IL-18 signaling (Xu et al., 2016). However, the youngest
age groups of adults (≤ 30 years) with SCZ were reported to have
elevated IL-18/IL-18BP ratios, reflecting unbound bioactive IL-18,
compared to older adults (≥ 50 years) (Palladino et al., 2012). While
IL-18 is a potent inflammatory cytokine, its activity can be attenuated
by IL-18 binding protein (IL-18BP) and modulated by the soluble forms
of IL-18R1 and IL-18 Receptor Accessory Protein (IL-18-RAP), although
the impact of these latter molecules on IL-18 activity is uncertain. Thus,
more studies of the IL-18 system in EOP that include pediatric patients
who have few confounders and that evaluate circulating levels of all IL-
18-related proteins are warranted.
Whether alterations in the IL-18 system are part of an intrinsic
immune dysregulation in psychosis-spectrum disorders or occur as a
consequence of confounders or psychosocial stress associated with
these disorders is largely unknown. Previous studies have shown that
inflammatory cytokines may be linked to negative symptom severity in
adults with psychosis, but such relationships have not been explored in
adolescents with EOP (Goldsmith et al., 2018). We hypothesized that
patients with EOP exhibits increased IL-18 system activity, and that the
activity is associated with levels of cortisol, perceived depressive
symptoms and negative symptoms. Therefore, in the present study we
investigated (i) whether adolescents with EOP exhibit alterations in
levels of IL-18-related proteins compared with healthy controls (HC),
(ii) whether unadjusted and adjusted analysis indicate that the potential
bioactive proportion of IL-18, as reflected by the IL-18/IL-18BP ratio, is
significantly related to stress as estimated by cortisol levels and self-
rated depressive symptoms, (iii) if having EOP contributes significantly
to the variance in IL-18/IL-18BP ratio, and whether the ratio is related
to the severity of negative symptoms.
2. Materials and methods
2.1. Study design
All participants were part of the ongoing longitudinal case-con-
trolled Thematically Organized-Psychosis Study for Youth (Youth-TOP),
at the University of Oslo and Oslo University Hospital, Norway.
Inclusion criteria were: (1) meeting the Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV) diagnostic criteria of a SCZ
spectrum disorder (SCZ, schizophreniform disorder, schizoaffective
disorder), an affective psychotic disorder (bipolar spectrum disorder,
major depressive disorder with psychosis) or other psychotic disorders
(psychosis not otherwise specified [NOS], delusional and brief psy-
chotic disorders); (2) aged between 12 and 18 years; (3) being able to
provide written consent; (4) being able to communicate in Norwegian.
Exclusion criteria were: (1) an intelligence quotient (IQ)< 70; (2)
previous moderate/severe head injury; (3) a diagnosis of substance-
induced psychotic disorder; or (4) having organic psychosis.
HC aged 12–18 years from the same catchment area as the patients
were randomly selected from the national population registry (www.
ssb.no) and invited by letter to participate. HC were excluded if they:
(1) currently met the criteria for, or had previously received treatment
for, any Axis I diagnosis; (2) had an IQ < 70; (3) had a history of or-
ganic brain disease; or (4) had a previous moderate/severe head injury.
Participation was based on informed consent and conducted in ac-
cordance with the Helsinki Declaration, version 2008 (sixth revision).
For those aged<16 years, consent was provided by parents or guar-
dians. The study was approved by the Regional Ethics Committee
(South-East) for Medical and Health Research Ethics (2009/691) and
the Norwegian Data Protection Authority (2003/2052).
2.2. Participants
We included patients (n=33) and HC (n= 63) enrolled between
January 2013 and October 2017, for whom fasting IL-18 and IL-18BP
levels and cortisol values were available. All were somatically healthy,
without known autoimmune or endocrine diseases, and with no co-
morbid substance abuse or dependence. At the time of blood sampling,
none had symptoms of an infectious disease.
2.3. Clinical variables
2.3.1. Diagnosis, global functioning, psychotic and depressive symptoms
The diagnostic evaluation was based on the Norwegian version of
the semi-structured clinical interview the Schedule for Affective
Disorders and Schizophrenia for School-Age Children-Present and
Lifetime Version (Kaufman et al., 1997). Global functioning was mea-
sured by the Children’s Global Assessment Scale (Shaffer et al., 1983).
Psychotic symptoms were assessed by the Positive and Negative Syn-
drome Scale (PANSS) (Kay et al., 1987). A Norwegian version of the
Mood and Feelings Questionnaire-Child version (MFQ-C) (Costello and
Angold, 1988) was used to assess pediatric depressive symptomatology,
because we wanted to capture perceived distress and negative affect.
The MFQ-C is a 34-item, self-rating questionnaire for children and
adolescents aged 6–17 years that has acceptable psychometric proper-
ties (Daviss et al., 2006). A cutoff of ≥29 points has been validated to
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identify major depressive episodes (Daviss et al., 2006). Two HC had
scores> 29, but were not removed, because preliminary analyses
showed that they did not influence the results. Among patients there
were no significant correlation between the PANSS negative sum scores
and the MFQ-C scores (r= 0.21, p= 0.275). HC were assessed using
the same psychometric tools as the patients, except for the PANSS.
2.3.2. Clinical and sociodemographic data
Information about smoking habits, duration of untreated psychosis
(DUP) and mother’s educational level (as a proxy measure of socio-
economic status) was obtained through clinical interviews. Smoking
habits were dichotomized as yes/no smoking on a daily basis at the
time of blood sampling. DUP was defined as the time interval in weeks
with persistent symptoms qualifying for a score of ≥4 on any of the
PANSS items—P1, delusions; P3, hallucinatory behavior; P5, grandi-
osity; P6, suspiciousness; or G9, unusual thought content—before the
subject received adequate treatment for psychosis. Participants were
weighed on calibrated digital scales under standard conditions, height
was measured using standard methods and BMI (kg/m²) calculated.
One HC was neither weighed nor measured. Imputations were made for
two patients and three HC with missing height values. In these cases, we
used the approximate height of an adolescent for a given age based on
the 50th percentile from the Norwegian reference height/age chart
(Juliusson et al., 2013).
2.3.3. Medication
Medication data were retrieved from medical records. Each patient’s
previous and current types and doses of AP were converted to a
chlorpromazine (CPZ)-equivalent dose as described by Andreasen et al.
(2010). Each type and dose were subsequently converted to CPZ years
using the formula (CPZ in mg) × (time on dosage measured in years),
and summed to provide a cumulative lifetime measure (CPZ years).
2.4. Biochemical variables
Venous blood samples were drawn between 8.10 and 11.20 a.m.
after an overnight fast. For hormone and biochemical analyses, serum
was separated within two hours. Cortisol was analyzed at the Hormone
Laboratory, Department of Medical Biochemistry, Oslo University
Hospital, Aker, Norway using a competitive luminescence im-
munoassay (Immulite 2000xpi kit from Siemens Healthineers,
Erlangen, Germany). Intra- and interassay coefficients were<10 %.
We defined cortisol levels> 860 nmol/L as outliers and removed two
HC and one patient from the analyses. Fasting serum total cholesterol
(TC), high-density cholesterol (HDL-C) and triglycerides (TG) were
analyzed at the Department of Clinical Biochemistry, Oslo University
Hospital, Oslo, Norway according to standard enzymatic-colorimetric
methods (Roche Diagnostics Norge AS, Oslo, Norway), and C-reactive
protein (CRP) was analyzed by particle enhanced immunoturbimetry
(Roche Diagnostics Norge AS, Oslo, Norway). CRP values below the
quantification limit of 0.6mg/L were treated as 0.6 mg/L in analyses
(61 % of patients and 80 % of HC had values< 0.6mg/L). One patient
had CRP=13.5 mg/L, representing an outlier value in this sample, but
was not removed because preliminary analyses showed that inclusion of
this patient did not influence the analyses of the IL-18 system.
We measured IL-18, its binding protein IL-18BP, and other secreted
components of the IL-18 system, IL-18RAP and IL-18R1. IL-18 (Cat#
DY318-05) and IL-18BP (Cat# DY119) levels were analyzed using an-
tibodies from R&D Systems (Stillwater, MN), while IL-18R1
(Cat#11102) and IL-18RAP (Cat#SEK10176) were analyzed using an-
tibodies from Sino Biological (Beijing, China). Samples were analyzed
in duplicate in a 384-well format using a combination of a SELMA
(Jena, Germany) pipetting robot and a BioTek (Winooski, VT) dis-
penser/washer. Absorption was read at 450 nm with wavelength cor-
rection set to 540 nm using an ELISA plate reader (BioTek). Intra- and
interassay coefficients were< 10 % for all. For immunoassays, blood
was taken using EDTA vials and the plasma was isolated the next
working day and stored at −80 °C. We calculated the ratio of IL-18 to
IL-18BP (IL-18/IL-18BP ratio), and used this in subsequent analyses
because it indicates the potential level of bioactive IL-18 (Novick et al.,
1999). IL-18/IL-18BP ratios> 800 were defined as outlier values, and
one HC and one patient were removed from the analyses.
2.5. Subgrouping according to cortisol and negative symptoms
Cortisol was chosen as a measurable neurochemical response to
stressors, the end product of HPA-axis activation. In subsequent ana-
lyses, we grouped participants into low or high cortisol groups based on
a cutoff at the 50th percentile of HC (low<352 nmol/L, high
≥352 nmol/L). We dichotomized the PANSS negative sum scores so
that 15 patients with scores ≥21 were grouped as having a high ne-
gative score, and 16 patients with scores< 21 as having a low negative
score, because a PANSS negative sum score of 21 corresponds to an
average negative item score of 3, defined as clearly pathological.
2.6. Statistics
Statistical analyses were performed using IBM SPSS Statistics (ver-
sion 25; IBM Corp., Armonk, NY, USA). All analyses were two-tailed
with the significance level set at p < 0.05. Data normality was assessed
with the Kolmogorov–Smirnov test. Independent Student’s t tests or chi-
square tests were used to compare continuous or categorical demo-
graphic variables between groups. Because it showed a skewed dis-
tribution, CPZ years was transformed to its natural logarithm and the
IL-18/IL-18BP ratios were square-root (sqrt) transformed. Independent
Student’s t tests were used to compare levels of IL-18 related proteins
between patients and HC. Bivariate correlation analysis was used to
explore relationships between sqrtIL-18/IL-18BP ratio and cortisol,
depressive symptoms and other clinical characteristics. Hierarchical
multiple linear regression analysis was then used to assess the unique
contributions of each factor to the explained variance in the sqrtIL-18/
IL-18BP ratio. Variables significantly (p < 0.05) correlated with the
dependent variable (smoking daily, cortisol, MFQ-C score and having
EOP [yes/no]) were introduced into the regression. Independent vari-
ables were entered one by one, with smoking daily at step 1, cortisol at
step 2, MFQ-C scores at step 3, and having EOP at step 4. Analyses were
conducted to check for assumptions of normality, linearity, multi-
collinearity and homoscedasticity. The hypotheses were prespecified
and not data driven, so p-values were not corrected for multiple testing.
3. Results
Demographics and descriptive information on participants are pre-
sented in Table 1. There were no significant differences in demographic
variables between patients and HC, except that more patients than HC
smoked on a daily basis (32 % vs. 7 %, p= 0.001), and patients had
significantly higher MFQ scores and lower CGAS scores compared to
HC. BMI and CRP did not differ significantly. There was no significant
difference in levels of cortisol between patients and HC, but the patients
had significantly higher levels of TG and TC/ HDL-C ratios.
3.1. IL-18 related protein levels in patients with EOP
Both levels of IL-18 and IL-18/IL-18BP ratios were significantly
higher in patients than in HC (Fig.1). In contrast, there were no sig-
nificant differences between patients and HC in levels of IL-18BP, IL-
18RAP or IL-18R1, see Table1. Similar patterns were seen when com-
paring AP-naïve patients (n=11) vs HC (IL-18, p= 0.016; IL-18/IL-
18BP ratio, p= 0.005; IL-18BP, IL-18R1, IL-18RAP, not significant),
and nonsmoking patients (n= 21) vs. HC (IL-18, p=0.011; IL-18/IL-
18BP ratio, p= 0.010; IL-18BP, IL-18R1, IL-18RAP, not significant),
and when controlling for sex (IL-18, p=0.001; IL-18/Il-18-ratio,
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p < 0.001; IL-18BP, IL-18R1,IL-18RAP, not significant).
3.2. IL-18 system activity and relationship to cortisol, depressive symptoms
and other clinical characteristics
Because the IL-18/IL-18BP ratio indicates the potentially bioactive
proportion of IL-18, this ratio was used in subsequent analyses. The IL-
18/IL-18BP ratio was significantly correlated with the level of cortisol
(r= 0.31, p= 0.003) and with depressive symptoms as measured by
MFQ-C score (r= 0.48, p < 0.001), and smoking daily (r= 0.38,
p < 0.001). In split file analysis, there was a significant correlation
between cortisol and IL18/IL-18BP-ratio in patients (r= 0.52,
p=0.003), but not in HC (r= 0.18, p= 0.176). Lipid levels (TC/HDL-
C: r= 0.14, p= 0.137; TG: r= 0.17, p=0.117) and AP medication
(r= 0.09, p= 0.475) were not significantly related to the IL-18/IL-
18BP ratio. All correlations are listed in Supplementary Table1. In ad-
justed analysis, both cortisol (R2 change=0.05, p=0.030) and MFQ-C
score (R2 change=0.09, p=0.001) were shown to contribute speci-
fically and significantly to the explained variance in IL-18-ratio, after
controlling for smoking (see Table 2). Controlling for time at blood
draw and BMI in the regression model did not change the results. In
fact, although BMI has been shown many times to be associated with
inflammation (Lumeng and Saltiel, 2011), BMI was not correlated with
the outcome variable neither in the complete sample (r= 0.10,
p=0.385), nor when patients (r= 0.002, p=0.907) and HCs
(r= 0.004, p=0.778) were analyzed separately.
3.3. Role of EOP and relationship with negative symptoms
After controlling for smoking, level of cortisol and MFQ-C, having
EOP did not provide a significant additional contribution to the ex-
plained variance (see Table 2). Among patients, total PANSS negative
score was not significantly correlated with IL-18/IL-18BP ratio (r =
-0.17, p= 0.363), and there was no significant difference in levels of IL-
18/IL-18BP ratio between patients having a low negative symptom
score compared to those having a high score (p=0.355).
4. Discussion
Our main finding was that adolescents with EOP had elevated
plasma levels of IL-18 and IL-18/IL-18BP ratios, without changes in IL-
18BP, IL-18RAP and IL-18R1. Serum cortisol and depressive symptoms
independently contributed to the explained variance in IL-18/IL-18BP
ratio, suggesting that stress, depressive symptoms and IL-18-pathway
activation may interact in adolescents with EOP.
Our findings in adolescents with EOP support findings in adults with
psychosis that showed elevated IL-18 levels (Orhan et al., 2018; Tanaka
et al., 2000; Wu et al., 2016; Xiu et al., 2012) and an imbalance in the
IL-18/IL-18BP ratio among younger adult patients (Palladino et al.,
2012). An increased IL-18/IL-18BP ratio may induce a pro in-
flammatory state because elevated levels of free IL-18 stimulate nuclear
factor-κB-dependent transcription of inflammatory cytokines, chemo-
kines, adhesion molecules and inflammatory enzymes (Barnes and
Karin, 1997). Further, elevated plasma IL-18 levels appear to promote
the development of several diseases including atherosclerosis (Whitman
et al., 2002) and diabetes mellitus (Oikawa et al., 2003), which occur
with increased prevalence in people with psychosis-spectrum disorders
(Olfson et al., 2015). Because such disorders may be confounders when
examining IL-18 and related inflammatory cytokines in adults with
psychosis, it is important to note that this is not the case in this po-
pulation of adolescents with psychosis: we found no impact of BMI or
lipid levels (TG and TC/HDL-C-ratio) on the IL-18/IL-18BP ratio in our
patients.
Instead, we found that the level of plasma cortisol explained 5 % of
the variance in levels of IL-18/IL-18BP ratio after controlling for
smoking, a finding that seems to be driven by the strong relationship
between cortisol and IL-18 activity shown in patients only. Several
clinical studies have suggested that acute and chronic psychosocial
stress affects the immune system in a pro-inflammatory direction, al-
though specific data on the IL-18 pathway are lacking (Bierhaus et al.,
2003; Marsland et al., 2017). However, our results are consistent with
those of experimental studies demonstrating that psychosocial stress
and HPA-axis activation augment IL-18 plasma levels and expression in
the adrenal gland (Sekiyama et al., 2006; Sugama et al., 2006). Al-
though IL-18 cannot cross the BBB, unless its integrity is compromised,
peripheral IL-18 could also reflect centrally increased levels associated
with NLRP3 inflammasome activity related to psychological stress, in
line with our finding that there is a strong relationship between IL-18
activity and levels of cortisol in patients with EOP. Interaction between
intrinsic vulnerability and external stressors is an established hypoth-
esis for the cause of SCZ (van Winkel et al., 2008), and individual
Table 1
Demographic and clinical characteristics of patients and healthy controls.
HC n Patients n T-test or X2
Mean (±SD) Mean (±SD) p-value
Demographics
Age 15.9 (1.4) 60 16.3 (1.4) 31 n.s
Male sex¹ 31/ 52 60 11/35 31 n.s
BMI 21.1 (3.1) 59 22.5 (4.9) 31 n.s
IQ 104.6 (12.9) 51 100.2 (13.4) 29 n.s
Mother’s education 15.3 (2.3) 53 15.1 (2.8) 31 n.s
Smoking daily¹ 4/7 60 10/32 31 0.001
Blood measures
IL-18/IL-18BP ratio 134.4 (125.6) 60 261.9 (193.0) 31 0.002
IL-18 (pg/mL) 768.6 (681.5) 60 1356.9 (798.8) 31 0.001
IL-18BPa (pg/mL) 6.3 (2.5) 60 5.8 (1.4) 31 n.s
IL-18RAP (pg/mL) 58.0 (27.6) 59 50.9 (13.2) 30 n.s
IL-18R1 (pg/mL) 0.97 (0.51) 60 0.92 (0.40) 31 n.s
Cortisol (nmol/L) 350.2 (123.5) 60 357.2 (140.3) 31 n.s
TC/HDL-C ratio 2.6 (0.7) 60 3.3 (1.0) 31 0.001
TG (mmol/L) 0.6 (0.3) 60 0.9 (0.5) 31 0.001
CRP 0.83 (0.79) 59 1.25 (2.32) 31 n.s
Clinical measures
CGAS 90.6 (6.1) 51 44.7 (9.6) 31 < 0.001
MFQ-C 6.7 (7.1) 50 26.9 (14.1) 29 < 0.001
DUP ² 15 (226) 31
Illness duration ² 1.2 (6.0) 26
PANSS
-pos 16.3 (4.7) 31
-neg 17.7 (6.9) 31
-gen 34.5 (8.5) 30
CPZ 146.6 (178.2) 31
CPZ years 8.9 (15.6) 31
AP-naïve ¹ 11/35 31






Diagnosis SCZ spectrum 15
Affective psychosis 2
Psychosis NOS 14
Key: HC, healthy controls; SD, standard deviation; BMI, body mass index; IQ,
Intelligence Quotient; TC/HDL-C ratio, total cholesterol/high-density lipopro-
tein cholesterol ratio; TG, triglycerides; CRP, C-reactive protein; CGAS,
Children’s Global Assessment Scale; MFQ-C, Mood and Feelings Questionnaire;
DUP, duration of untreated psychosis in weeks; Illness duration in years;
PANSS, Positive and Negative Symptom Scale; -pos, total positive score; -neg,
total negative score; -gen, total general score; CPZ, chlorpromazine equivalents;
CPZ years, lifetime exposure in chlorpromazine equivalents; AP-naïve,
Antipsychotic medication-naïve; No AP, no use of antipsychotic medication at
time of blood sampling; SCZ, schizophrenia; NOS, psychosis not otherwise
specified. ¹n /%. ² median (range).
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Fig. 1. (a-d) Group differences between patients and healthy controls in levels of (a) IL-18; (b) IL-18BP; (c) IL-18RAP; (d) IL-18R1. (e-f) Scatter plots shows
associations between levels of IL-18 and IL-18 BP in (e) healthy controls and (f) patients, with a significant negative correlation in patients only (r= -0.48,
p= 0.007). Solid lines represent linear regressions.
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differences in immune reactivity to stress serve as predictors of future
depression (Pace et al., 2006). Our finding that cortisol contributes to
IL-18/IL-18BP ratio variability in EOP supports that psychosocial stress
may be linked to low-grade inflammation in psychosis (Howes and
McCutcheon, 2017).
Enhanced systemic inflammation is also associated with depression
in adults (Kohler et al., 2017) and adolescents (Mills et al., 2013). In
addition, IL-18-deficient mice exhibited resilience to depression-like
behavior promoted by chronic stress (Kim et al., 2017), indicating that
IL-18 plays a role in the development of stress-induced depression.
Moreover, most clinical studies have found a positive correlation be-
tween levels of IL-18 and depressive symptoms in patients with de-
pression (Inserra et al., 2019) and psychosis (Xiu et al., 2012), even
though one study reported a negative correlation between IL-18 and
depressive symptoms in middle aged patients with chronic psychosis
(Bossu et al., 2015). Our finding of a positive correlation between IL-
18/IL-18BP ratio and MFQ-C score may further support a role for IL-18
in the pathophysiology of depression. However, because depression is
also associated with bidirectional dysregulation of the HPA axis and
immune system alterations, longitudinal studies are needed to dissect
these relationships.
Although a positive relationship between negative symptoms and
tumor necrosis factor, IL-6 and CRP has been demonstrated in patients
with psychosis (Garcia-Rizo et al., 2012; Goldsmith et al., 2018), in the
present study the IL-18/IL-18BP ratio did not correlate significantly
with negative symptoms among adolescents with EOP. This is con-
sistent with Zhang’s observation that there was no association between
serum IL-18 and negative symptoms in patients with chronic SCZ
(Zhang et al., 2016).
The present study has several strengths, including a young and
clinically well-characterized sample with few confounders, and a pro-
portion of 35 % AP medication-naïve patients. In addition, all partici-
pants were from the same catchment area with similar ethnicity and
duration of mother’s education (a proxy measure for sociodemographic
status). However, the study has some limitations. Its cross-sectional
nature did not allow exploration of cause and effect. Blood for mea-
suring plasma cortisol was drawn at different time points between
08.10 and 11.20 a.m. However, timing effects were not found to in-
fluence analyses. Patients with psychosis have dysregulations in circa-
dian rhythmicity (Seney et al., 2019), including alterations in sleep-
wake cycle and rhythmic hormonal profiles, such as cortisol, in addition
to increased subjective reactivity to external stressors. Consequently, it
is unclear to what extent levels of cortisol in our study can be inter-
preted as a function of psychological stress, and our data have to be
interpreted with caution. We therefore need longitudinal studies with
better measures of perceived psychological stress and more objective
measures of stress response in relation to the IL-18 system. Lastly, while
we here focused on the IL-18 system, there is a need for studies of other
parts of the immune system in EOP, and the current findings suggest
that cytokine network studies would be of great value.
5. Conclusion
We found elevated levels of plasma IL-18 and elevated IL-18/IL-
18BP ratios in adolescents with EOP. Cortisol and depressive symptoms
independently contributed to the explained variance in the IL-18/IL-
18BP ratio. Our findings indicate that inflammatory pathways are al-
ready activated at an early age in patients with psychosis, with IL-18 as
a potentially important player. Our findings also suggest an interaction
between stress, inflammation and depressive symptoms in adolescents
with EOP.
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